DK3439661T3 - Fremgangsmåder til behandling af øjenlidelser - Google Patents
Fremgangsmåder til behandling af øjenlidelser Download PDFInfo
- Publication number
- DK3439661T3 DK3439661T3 DK17718304.3T DK17718304T DK3439661T3 DK 3439661 T3 DK3439661 T3 DK 3439661T3 DK 17718304 T DK17718304 T DK 17718304T DK 3439661 T3 DK3439661 T3 DK 3439661T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- treatment
- eye disorders
- disorders
- eye
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662319648P | 2016-04-07 | 2016-04-07 | |
PCT/US2017/026385 WO2017177024A1 (en) | 2016-04-07 | 2017-04-06 | Methods of treating ocular conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3439661T3 true DK3439661T3 (da) | 2021-10-18 |
Family
ID=58549326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17718304.3T DK3439661T3 (da) | 2016-04-07 | 2017-04-06 | Fremgangsmåder til behandling af øjenlidelser |
Country Status (20)
Country | Link |
---|---|
US (2) | US10709707B2 (da) |
EP (2) | EP3970724A1 (da) |
JP (2) | JP7090551B2 (da) |
KR (2) | KR102512777B1 (da) |
CN (3) | CN114533737A (da) |
AU (1) | AU2017248276B2 (da) |
BR (1) | BR112018070497A2 (da) |
CA (1) | CA3020170A1 (da) |
DK (1) | DK3439661T3 (da) |
EA (1) | EA201892265A1 (da) |
ES (1) | ES2893126T3 (da) |
IL (3) | IL299204A (da) |
MX (2) | MX2018012230A (da) |
MY (1) | MY199237A (da) |
NZ (1) | NZ746468A (da) |
PH (1) | PH12018502154A1 (da) |
PT (1) | PT3439661T (da) |
SG (1) | SG11201808650QA (da) |
TW (2) | TW202320785A (da) |
WO (1) | WO2017177024A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
DK3209295T4 (da) | 2014-10-20 | 2024-02-26 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
KR102512777B1 (ko) * | 2016-04-07 | 2023-03-23 | 오이스터 포인트 파마 인코포레이티드 | 안구 장애의 치료 방법 |
TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
CN112638364A (zh) | 2018-07-10 | 2021-04-09 | 奥伊斯特普安生物制药公司 | 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合 |
TW202206078A (zh) | 2020-04-28 | 2022-02-16 | 美商奧伊斯特普安生物製藥公司 | 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染 |
KR20240021783A (ko) * | 2021-05-07 | 2024-02-19 | 오이스터 포인트 파마 인코포레이티드 | 벡터 및 니코틴 작용제 병용 요법 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
AU2002341327A1 (en) | 2001-11-29 | 2003-06-10 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
AU2003269413A1 (en) | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
US20060270592A1 (en) | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
BRPI0515932A (pt) | 2004-10-15 | 2008-08-12 | Pfizer Prod Inc | composições e métodos para distribuição intranasal, bucal, sublingual e pulmonar de vareniclina |
WO2006100075A2 (en) | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
TWI454262B (zh) | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
EA016494B1 (ru) | 2007-02-02 | 2012-05-30 | Пфайзер Продактс Инк. | (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ |
WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
CA2716863A1 (en) | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
US20110263629A1 (en) | 2008-09-05 | 2011-10-27 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
KR20110091501A (ko) * | 2008-10-14 | 2011-08-11 | 싸이코제닉스 아이엔씨. | 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도 |
ES2820857T3 (es) * | 2008-12-01 | 2021-04-22 | Oyster Point Pharma Inc | Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina |
US9145396B2 (en) * | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
TW201024283A (en) | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
WO2010147938A2 (en) * | 2009-06-17 | 2010-12-23 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
US8821457B2 (en) | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
KR102043077B1 (ko) | 2011-10-20 | 2019-11-11 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성을 예측하는 바이오마커 |
EP3029463A1 (en) | 2011-11-30 | 2016-06-08 | DiagnosTear Ltd | Dry eye diagnostic |
DK3209295T4 (da) * | 2014-10-20 | 2024-02-26 | Oyster Point Pharma Inc | Fremgangsmåder til behandling af øjenlidelser |
KR102512777B1 (ko) | 2016-04-07 | 2023-03-23 | 오이스터 포인트 파마 인코포레이티드 | 안구 장애의 치료 방법 |
-
2017
- 2017-04-06 KR KR1020237000103A patent/KR102512777B1/ko active IP Right Grant
- 2017-04-06 BR BR112018070497A patent/BR112018070497A2/pt active Search and Examination
- 2017-04-06 DK DK17718304.3T patent/DK3439661T3/da active
- 2017-04-06 TW TW112102845A patent/TW202320785A/zh unknown
- 2017-04-06 JP JP2018553080A patent/JP7090551B2/ja active Active
- 2017-04-06 ES ES17718304T patent/ES2893126T3/es active Active
- 2017-04-06 CA CA3020170A patent/CA3020170A1/en active Pending
- 2017-04-06 WO PCT/US2017/026385 patent/WO2017177024A1/en active Application Filing
- 2017-04-06 CN CN202210034408.5A patent/CN114533737A/zh active Pending
- 2017-04-06 CN CN202210040168.XA patent/CN114432313A/zh active Pending
- 2017-04-06 KR KR1020187032218A patent/KR102485299B1/ko active IP Right Grant
- 2017-04-06 EP EP21189296.3A patent/EP3970724A1/en active Pending
- 2017-04-06 IL IL299204A patent/IL299204A/en unknown
- 2017-04-06 PT PT177183043T patent/PT3439661T/pt unknown
- 2017-04-06 TW TW106111559A patent/TWI790997B/zh active
- 2017-04-06 MX MX2018012230A patent/MX2018012230A/es unknown
- 2017-04-06 EA EA201892265A patent/EA201892265A1/ru unknown
- 2017-04-06 CN CN201780034734.3A patent/CN109310692B/zh active Active
- 2017-04-06 NZ NZ746468A patent/NZ746468A/en unknown
- 2017-04-06 MY MYPI2018001700A patent/MY199237A/en unknown
- 2017-04-06 EP EP17718304.3A patent/EP3439661B1/en active Active
- 2017-04-06 SG SG11201808650QA patent/SG11201808650QA/en unknown
- 2017-04-06 AU AU2017248276A patent/AU2017248276B2/en active Active
- 2017-04-06 US US16/091,830 patent/US10709707B2/en active Active
-
2018
- 2018-10-03 IL IL262102A patent/IL262102B/en unknown
- 2018-10-05 MX MX2021010399A patent/MX2021010399A/es unknown
- 2018-10-05 PH PH12018502154A patent/PH12018502154A1/en unknown
-
2020
- 2020-04-17 US US16/852,225 patent/US20200345734A1/en active Pending
-
2022
- 2022-01-24 IL IL290069A patent/IL290069B2/en unknown
- 2022-06-14 JP JP2022095460A patent/JP2022120125A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
DK3386511T3 (da) | Fremgangsmåder til behandling af huntingtons sygdom | |
DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
DK3448999T3 (da) | Oligonukleotider til behandling af øjensygdom | |
DK3516060T3 (da) | Antisense-oligonukleotider til behandling af øjensygdom | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3399962T3 (da) | Oftalmisk sammensætning til behandling af tør øjensygdom | |
DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
DK3265085T3 (da) | Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser | |
DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
DK3439661T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
IL267229A (en) | Methods of treating ocular disorders |